Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) EBIT Margin (2018 - 2025)

Catalyst Pharmaceuticals' EBIT Margin history spans 11 years, with the latest figure at 89.37% for Q4 2025.

  • For Q4 2025, EBIT Margin fell 13368.0% year-over-year to 89.37%; the TTM value through Dec 2025 reached 10.11%, down 2957.0%, while the annual FY2025 figure was 10.11%, 2957.0% down from the prior year.
  • EBIT Margin reached 89.37% in Q4 2025 per CPRX's latest filing, down from 44.66% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 53.79% in Q2 2022 to a low of 89.37% in Q4 2025.
  • Average EBIT Margin over 5 years is 31.39%, with a median of 42.63% recorded in 2021.
  • Peak YoY movement for EBIT Margin: soared 7577bps in 2024, then tumbled -13368bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 33.26% in 2021, then surged by 52bps to 50.7% in 2022, then fell by -26bps to 37.71% in 2023, then increased by 18bps to 44.31% in 2024, then tumbled by -302bps to 89.37% in 2025.
  • Per Business Quant, the three most recent readings for CPRX's EBIT Margin are 89.37% (Q4 2025), 44.66% (Q3 2025), and 45.24% (Q2 2025).